ReviewTherapeutic advances in medical oncology2016
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness.
Review in Therapeutic advances in medical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.Clinical and translational medicine · 2024Trial
- The impact of cancer-related diarrhea on changes in cancer therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Observational
- Review
- Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs.Frontiers in oncology · 2024Review
- Neratinib for HER2-positive breast cancer with an overlooked option.Molecular medicine (Cambridge, Mass.) · 2023Review
- Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study.Frontiers in pharmacology · 2023Article
- Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.Frontiers in pharmacology · 2022Review
- Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.Frontiers in molecular biosciences · 2022Review
- Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.Current heart failure reports · 2021Review
- Peptidomimetic-based antibody surrogate for HER2.Acta pharmaceutica Sinica. B · 2021Article
- Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.Breast cancer : basic and clinical research · 2021Review
- Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report.OncoTargets and therapy · 2020Article
- Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2Breast cancer research : BCR · 2019Article
- Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.Cancer chemotherapy and pharmacology · 2018Article
- Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Article
- Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs.Experimental and therapeutic medicine · 2018Review
- Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Frontiers in oncology · 2018Review
- Review
- Advances in the management of HER2-positive early breast cancer.Critical reviews in oncology/hematology · 2017Review
- Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of HER-2-positive breast cancer has improved significantly with the use of targeted agents to the HER-2 signaling pathway. Despite the improved survival achieved with the use of trastuzumab and chemotherapy in both the adjuvant and metastatic setting, patients may still recur or progress; whilst preclinical data demonstrate that these cancer cells remain addicted to the HER-2 oncogene. Neratinib, an oral small molecule tyrosine-kinase inhibitor has efficacy in the metastatic and adjuvant setting of patients who have previously received trastuzumab-based treatment. Diarrhea, being a class effect of tyrosine-kinase inhibitor, is the most common side effect seen following neratinib administration, but recent data suggests that a prophylactic loperamide regimen can reduce the incidence of grade 3 diarrhea. Phase I through to III clinical trials of neratinib will be reviewed, with discussion of the postulated mechanism underlying diarrheal events and its management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.